Clay Sieagall career journey.

Just at 19 years, Clay Sieagall watched as his father struggled with cancer, this went on for almost four years. This experience was a turning point for Clay as he developed the need to help patients suffering from cancer and their family members. This lead to the establishment of Seattle Genetics which sees to provide treatment for patients who have cancer. The company was established around 1998 and has since grown and advanced in cancer therapies. Currently, Clay serves as the CEO, president and also as a board member at Seattle Genetics.

As a businessman, one thing that Clay Sieagall would recommend for one to do is to learn from other people, interact people and be sure to learn a thing or two everyone has something to offer. At 20 clay though he knew everything but with time, he has discovered that there is so much he is yet to learn and this has helped him to grow and remain productive.

Seattle Genetics has been in the industry for several years now, one thing that has helped the company remain relevant is the collaborations. Clay is always seeking to work with different organizations. According to Clay, his helps one to grow. In Clay’s case he has identified there is a need to include medicine and technology and thus works closely with technology companies to come up with treatments that will be more effective

Under his leadership the company has managed to get into collaborations that have helped raise the standards of the company, the value of the company has continued to increase over the years, and their aim to provide medications for patients who have cancer has not been undermined. The company has managed to acquire approval from the FDA for the ADC treatment this is a huge step in providing hope for patients all over the world.

Clay’s Leadership skills are exceptional, and his work in the company is undeniable, all we can do now is hope for the company’s growth and more advanced and better innovations in the medical sector.

Clay Sieagall received his zoology degree from the University of Maryland.

Eric Lefkofsky is Creating the Clinical Study Singularity

Eric Lefkofsky is one of the biggest names in medical philanthropy throughout the United States. Having donated tens of millions of dollars to cancer research alone, the entrepreneur has become one of the most appreciated philanthropists of his age. But unlike many independently wealthy philanthropists, Lefkofsky likes to take a more hands-on approach to his largesse. In 2016, Lefkofsky founded a company, Tempus, which seeks to revolutionize the way in which cancer is treated through putting the most powerful information available into the hands of oncologists.

After a close family member was diagnosed with cancer, Lefkofsky was dismayed to discover that many oncologists working in the field today have less access to vital information than the typical truck driver. This disturbing realization prompted Lefkofsky to begin looking into ways in which better sources of data and analytic intelligence can be put into the hands of treating physicians in real-time. He eventually came to the conclusion that such new technologies as CRISPR and human gene sequencing were not being used to anywhere near their full potential. These new technologies were a potential treasure trove of data that could be used by oncologists in real time to formulate far more effective treatment protocols for each of their patients and learn more about Eric.

Eventually, the idea for Tempus began coalescing in Lefkofsky’s head. It would be a means to effectively allow oncologists to answer the same questions, even with complex data sets, that would have previously only been possible to effectively answer through the use of large-scale clinical studies. Even a decade ago, such a platform would have been impossible to create. But today, through the use of such means as artificial intelligence and the vast computing power contained in the cloud, it is possible to sift through mind-boggling volumes of data, teasing out the subtle patterns and correlations that exist between seemingly unrelated factors and more information click here.

Lefkofsky believes that this new technology will effectively enable physicians to gain a near-infinite granularity in their understanding of how patients react to medicines and treatments. It will eventually allow doctors to custom design treatment protocols to each individual patient.

More Visit: https://www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html

Oncotarget’s E-Cigarette Study

A study has been conducted by medicine man Ifran Rahman that has shed light on the unfortunate notion that e-cigarettes much like regular cigarettes are hazardous to health. Specifically it has been identified that the vapors release inflammatory proteins that are hazardous to gum tissue at a molecular level. In addition to this, the coupled flavor vapors are also hazardous to the gum tissue. When vapors are burned, the damage occurs. This is unfortunate mostly in that many people have the opinion that e-cigs are a healthy substitute to regular cigarettes when in fact it has become quite clear that they are not. Though they affect health in different ways, users are risking their well being by using either of them. They both also contain nicotine which is both addictive and another hazard that could lead to several oral diseases. Check the journal at SCImago Journal & Country Rank.

Ifran Rahman hopes that e-cig companies will start to release all the ingredients of their products to full public view so that he may uncover more possible secrets of the e-cig companies. Up to this point it seems that the companies have not been fully honest in documenting the ingredients required to produce such hazardous products. The goal of the studies conducted by Ifran Rahman are simply to educate the public more adequately on the effects of using such products being that they have been a bit ignorant to the facts up to this point. Not to the public’s discredit. As Ifran Rahman continues to study the products he hopes the companies will be more willing to share private information and better educate the public on what it is that they’re unknowingly consuming.

Oncotarget is a detailing of pathological routes of diseases, cancer studies, therapy studies, and patient management studies all coupled together in a peer to peer review. The efforts of such collections is to produce better practices in the medical industry via improved patient care as well as development of more effective treatments and management programs. The trialed evidence also goes over the effectiveness of treatments by practicing medical professionals. Visit Oncotarget’s profile page at facebook.com